Freddie Bray

TL;DR: It is expected rates in high‐risk countries to continue to decrease, as the population seroprevalence of hepatitis B virus (HBV) continues to decline, and targeted screening and treatment of the hepatitis C virus (HCV), treatment of diabetes and primary prevention of obesity, will be key in reducing future liver cancer incidence.

TL;DR: It is suggested that the major determinants of the observed trends vary among the countries and may include earlier detection through screening in countries where this has been introduced, but also improvements in therapy, in countries with or without screening.

TL;DR: A large proportion of TC cases diagnosed in high-resource countries in the last two decades are likely to be due to diagnostic changes, and this proportion has progressively increased over time, and it is likely to grow further in the future.

TL;DR: The potential cumulative effect of scaled up global vaccination and screening coverage on the number of cervical cancer cases averted over the 50 years from 2020 to 2069 is quantified and outcomes beyond 2070 are predicted to predict the future incidence rates and burden of cervicalcancer.

TL;DR: Gains in the control of liver cancer are at risk of being reversed by the growing obesity and diabetes epidemics, suggesting diabetes treatment and primary prevention of obesity will be key in reducing liver cancer in the longer‐term.